In addition, we examined drug databases for potential drugs targeting the proteins identified for PCa, BRCa and LCa treatments, such as Bioymifi (a binder of TNFRSF10B) for PCa, alpha-Tocopherol succinate (an inhibitor of GSTP1) for PCa, and Theophylline for BRCa. This evidence concerns the gene TNFRSF10B and posterior cortical atrophy.